G-CSF filgrastim is frequently used to mobilise CD34 þ cells in donors before PBSC collection. Several observational reports raised concerns regarding an elevated risk of haematological malignancies after G-CSF administration. It was found that treatment with G-CSF of PBSC donors induced chromosomal tetraploidy in a small subset of mature myeloid cells in the blood, 1 epigenetic and genetic alterations in lymphocytes 2 and aneuploidy. 3 In 2006, Bennett et al. 4 reported two cases of AML identified in the sibling donors, whose recipients also suffered with AML, among 200 individuals who had received filgrastim before collection of PBSC for allogeneic transplantation. In a large retrospective EBMT analysis, Halter et al. 5 observed 20 haematological malignancies (3.92/10 000), of which 12 were after donating PBSC; however, the observed incidence rate did not exceed the expected incidence in an age-and sex-adjusted general population, and there was no relationship with the type of haematological malignancy in the recipients and donors donating for siblings.
We decided to conduct an analysis of follow-up policy and haematological malignancy incidence in related sibling donors of allogeneic PBSC mobilised with G-CSF filgrastim in the period of 2001-2010 at our transplant centre (TC), and to compare the results with those of unrelated donors of the Czech National Marrow Donor Registry (CNMDR).
At both institutions, the PBSC donors were mobilised with the filgrastim 10 mg/kg/day s.c. injection for 5 consecutive days, and there was short-term 1-year followup surveillance of donors set up in 2001. The donors were instructed to keep 1 week, 1, 6 and 12 months follow-up visits at the local CNMDR donor centre or their personal physician. This 'passive' system of follow-up was replaced with an 'active' one in 2003 at the CNMDR and in 2008 at our TC, and since then our transplant coordinator and CNMDR Donor Centres have been responsible for careful surveillance of the donors and actively consult donors in case of missed follow-up visits. Since 2005, a prolonged 5-year follow-up system with annual visits has been established within CNMDR. Recently, a questionnaire letter was sent to our TC-related donors to retrospectively get information about their health status. Donor safety and management procedures implemented within the CNMDR and at our TC reflected those of World Marrow Donor Association (WMDA) and those of Joint Accreditation Committee-ISCT and EBMT (JACIE).
Basic statistical univariate analyses (Fisher's exact two-tailed test for categorical data and unpaired t-test for continuous data) were performed using statistical software (GraphPad Software, La Jolla, CA, USA), and the Pvalues o0.05 were considered as indicating statistically significant differences between analysed groups of donors.
In the period of 2001-2010, 125 related PBSC donors (median age 50 (16-75) years, 55% males) were registered into the short-term 1-year follow-up, and 52 donors responded to the retrospective long-term health-status questionnaire. Because 41/125 (33%) PBSC sibling donors were lost from the follow-up, mainly due to their individual personal reasons, surveillance information about 84 of them was available in total, which corresponded to 337 PBSC person-years of observation.
In all, 188 unrelated CNMDR PBSC donors (median age 31 (19-55), 31% males) were registered into the short-term 1-year follow-up in 2001-2010, and 121 of them into the prolonged 5-years follow-up, as well. Only 10/188 (5%) unrelated donors were lost from the follow-up. Thus surveillance information about 178 CNMDR donors was available in total, which corresponds to 444 PBSC person-years of observation.
The ratio of 'lost from follow-up' donors was significantly different between the 'passive' and 'active' follow-up systems at both institutions and between unrelated and related donors. For more details see Table 1 .
There was no observed malignancy in a group of 178 PBSC-unrelated CNMDR donors, in 444 PBSC personyears, respectively. There were two haematological (AML and non-Hodgkin lymphoma) and two other malignancies (renal and colon cancer) observed in a group of 84 PBSC sibling donors with median age 50 (16-75), in 337 PBSC person-years, respectively. The respective incidences of the two haematological malignancies per 100 000 person-years of follow-up was 593 cases, compared with the expected incidence rate 143 per 100 000 in the general population using the age-adjusted SEER incidence rates for haematological malignancies (AML and nonHodgkin lymphoma) for both-sexes non-Hispanic white race age 20-75 years. 6 For more details about the donor, malignancy and the recipient see Table 2 . Unfortunately, we were not able to evaluate and compare the results with related BM donors, as only very limited data were available in this group.
The results of this observation, however, must be considered in the larger context. The analysis was performed on small number of donors and there was limited donor follow-up in the related donor group.
Although the same active system of donor surveillance was implemented both at CNMDR and our TC, the cooperation with related donors and their follow-up was more difficult to perform, mostly due to various psycho-social reasons. Sibling donor age was significantly higher, which is also an important factor accounting for the higher incidence of malignancies in this group, and the fact that siblings of persons with leukaemia have a 2-5-fold increased annual incidence of haematological malignancies, 7-9 must be also considered. In conclusion: the risk of haematological malignancies development among PBSC donors is real and related donors appear more vulnerable compared with those unrelated. The contribution of filgrastim exposure to the development of acute leukaemia and lymphoma needs to be further observed. An active, prospective and prolonged (probably life-long) donor follow-up system is necessary both in unrelated and related donors to ensure important data availability. Standardised international follow-up should be encouraged. 
